AdventuresinCapitalism on raised rates on REITS (link)
Look at the charts of various smaller REITs that aren’t being propped up with broad market ETF inflows. These things are getting nuked—particularly in the retail sector.
I did the math of the example mentioned:
“To Buy or Not To Buy” – Credit-Suisse on M&A (link)
Companies that act early in an M&A cycle tend to generate higher returns than those that act later.
Empirical analysis shows that M&A creates value in the aggregate, but that the seller tends to realize most of
Peter Clark and Roger Mills, finance experts who focus on M&A, found that deals they call “opportunistic,” where a weak competitor sells out, succeed at a rate of around 90 percent. “Operational” deals, or cases where there are strong operational overlaps, also have an above-average chance of success.
Jim Chanos Interview (link)
Neil Woodford himself (link)
We are more upbeat on the outlook for the UK economy than many commentators – the market consensus, in our view, has become too bearish in the aftermath of the Brexit vote
Brooklyn Investor commenting Buffett’s CNBC Interview (link)
… but history shows that the market does in fact use interest rates to value the stock market however theoretically wrong it may be, and the greatest investor of all time does so too.
The german chemical and pharmaceutical company Bayer want’s to buy U.S. agrochemical company Monsanto (link: press release Bayer)
Bayer has made an all-cash offer to acquire all of the issued and outstanding shares of common stock of Monsanto Company for USD 122 per share or an aggregate value of USD 62 billion
Moody’s reviews Bayer’s ratings for downgrade on Monsanto acquisition announcement (link Moodys)
Random people throwing around random numbers (link)
Some Bayer shareholders don’t like the deal (link)
That could be a problem, with some saying Bayer’s proposal, at 15.8 times Monsanto’s earnings before interest, tax, depreciation and amortisation (EBITDA) for the year ended Feb. 29, is already a stretch for the German company.
Let’s take a look at what Bayer is planning to pay for 62 bn
I looked at Monsantos 2015 annual report, which besides some nice photos of families marvel at corn presents us this numbers: (link)
Their 2024 Bond yields 3.24% (link morningstar)
From the 2Q2016 report (link)
Monsanto updated its fiscal year 2016 as-reported EPS guidance to be in the range of $3.72 to $4.48 per share, primarily due to a change in the expected timing for the accounting of restructuring expense. The company confirmed ongoing EPS guidance in the range of $4.40 to $5.10 per share.
Let’s be optimistic and assume that they can reach the $5.10 per share. At a price of 122 USD this would be a PE-ratio of 23.9 – not that cheap.
Like in mostly M&A activities this is an interesting case with some uncertainties and some chances. I don’t have deeper insight into this one but I will follow this from the sideline and hopefully will learn something from it. I’m planing to look at Bayer next.
Disclaimer: The content contained on this site represents only the opinions of its author(s). I may hold a position in securities mentioned on this site. In no way should anything on this website be considered investment advice and should never be relied on in making an investment decision. As always please do your own research!